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To acquire the energy that is needed for synthesis of products essential for cellular 
functions and survival, an integrated network of chemical reactions exists in virtually all 
cells in the body (adapted from Sauerwein (1)). This network consists of countless 
reactions that constitute fluxes of metabolites and ions within the cell and is fuelled by 
extensive traffic of energy-rich and structural compounds between cells and/or organs. 
The reactions that maintain the network are tightly regulated and mediated by proteins 
(enzymes/transporters) whose activities can be regulated at different levels. The proteins 
involved are synthesized according to their encoding DNA sequences: copies (RNA) are 
made from DNA (transcription) and, subsequently, the base-pair sequences in RNA are 
translated into the amino acid sequence of the protein (translation). The proteins formed 
may subsequently be modified by several mechanisms to modulate their 
(enzymatic/transport) activities. Disturbances within the integrated network, for instance 
due to dysfunction of a certain protein, often results in adaptive responses, that 
sometimes lead to predictable, but more frequently to unexpected redirections of the 
metabolic fluxes (2;3). Causes of such disturbances can be various. For instance, they 
can be due to an inherited defect in the production of a certain enzyme, as is the case in 
glycogen storage diseases and certain β-oxidation defects. Such disturbances can also be 
acquired, as for instance occurs in diabetes mellitus type II. It is also possible to 
interfere in certain processes by pharmacological means, e.g., by drug-mediated 
blockade of enzyme activity or induction of transporter activity.   
The consequences of disturbances in integrated networks can sometimes 
relatively easy be evaluated by measuring concentrations of products of the network in 
tissues or blood samples (clinical chemistry, now often referred to as metabolomics). 
With the introduction of molecular biological techniques, it became more and more 
common to measure expression levels of genes participating in the network (genomics, 
transcriptomics) as a means to predict metabolic adaptations. Changes in levels of the 
different proteins contributing in the network can also be quantified (proteomics) as well 
as their modifications (e.g., kinome profiling). However, all these “static” measurements 
refer to the status of a particular network at a certain point of time (“snapshot”) and, by 
definition, do not provide insight in the magnitude of the metabolic flux through the 
pathway. In view of the fact that many of the relevant metabolic processes show strong 
diurnal variations, interpretation of the static data often results in incorrect conclusions.  
In addition, data are often generated in cell culture experiments or in isolated organs. 
Although such results definitively provide valuable information about the network 
studied, the results can by definition not directly be extrapolated to in vivo metabolism in 
a whole organism. With the introduction of flux measurements in vivo (fluxomics) by 
others and by us (this thesis) it became possible to quantify changes in metabolic 
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networks over time (“real-time movie”), i.e., from substrate to product in conscious, 
freely moving animals as well as in humans. 
The fluxomic approaches described in this thesis were initially developed for use 
in rat models (Chapter 5) but, due to the possibilities of genetic modification, mice 
became the animal specie of choice for our experiments. This change of animal model 
forced us to adapt both the experimental and analytical protocols, as detailed in  
Chapter 6. These protocols have successfully been employed in studies addressing 
insulin sensitivity of hepatic and peripheral glucose metabolism in mouse models of 
diabetes (Chapter 7) and the kinetics of glucose absorption (Chapter 8). Finally a novel, 
simple technique has been developed that allows to determine insulin sensitivity in mice 
over time (chapter 9). Applications of these techniques can be found in a series of 
recently published articles from our laboratory ((4-19) and manuscripts in preparation of 
Boer et al., Fijlstra et al., Houten et al., Prawitt et al., Stroeve et al. , Zonneberg et al.). 
Furthermore, protocols have been adapted/developed and applied to assess de novo 
lipogenesis and fatty acyl chain elongation ((20-22) and manuscripts in preparation of 
Frayn et al., Koolman et al., Stroeve et al.,) and several aspects of cholesterol 
metabolism ((21;23-25) and manuscripts in preparation of Brufau et al., Herrema et al., 
Stroeve et al., van Meer et al., van der Wulp et al.)   
 
 
EXPERIMENTAL PROTOCOLS  
Novel and existing mouse models allowed to study metabolic fluxes in conditions of 
inherited disorders like MCADD (6;7) and acquired metabolic diseases like type 2 
diabetes mellitus (12;14). Application of the stable isotope methodologies of choice in 
mice posed several physical and analytical problems. Experimental set-ups used for rat 
studies could not always be used for mice. We constructed a new type of experimental 
cage that enabled frequent collection of blood and urine from unanaesthetized mice (see 
Appendix 1). Furthermore, constant infusion protocols had to be developed, including a 
miniaturized mixing moiety for the insulin-clamp experiments (see Appendix 1). 
Turnover rates of carbohydrate metabolism are, when expressed per kg body weight, 
considerably higher in mice compared to rats and humans. Isotope infusion rates had to 
be adjusted taking into account that the maximal flow rate of infusion is relatively low in 
mice. The adapted infusion rates were employed in healthy and in hyperglycemic mouse 
models (14;16). In mouse models suffering from hypoglycemia, as used by Derks et al. 
and Herrema et al. (6;7), the total carbohydrate load during the experiment was reduced 
by 50% to avoid the induction of changes in blood glucose levels. Because this reduction 
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in input rate did not influence the calculated carbohydrate fluxes in the healthy control 
groups nor analytical precision, it became our standard protocol. 
The small amount of urine that is produced by mice was collected effectively in 
timed intervals on filter paper placed under the wired floor of the designed cages. With 
the introduction of blood sampling on filter paper (bloodspot) it was possible to reduce 
the total volume of blood taken during the experiments. Sample collection on filter paper 
is commonly used in neonatal screening of human newborns (26) and for monitoring of 
therapy in patients with either inborn or acquired metabolic diseases such as 
phenylketonuria and diabetes (27-31). In contrast to Von Schenck (28) and Abyholm 
(31), who used sulfosalicylic acid and perchloric acid solutions to elute glucose from the 
bloodspots, we have chosen for a mixture of water and ethanol because of the rapid 
evaporation of this solution in derivatization procedures. Bloodspot sampling has a 
number of beneficial aspects for our purposes: 1) the dried samples can be stored at 
room temperature for a relatively long period (weeks), 2) the dried samples can be 
transported easily 3) the sampling procedure can be used for experiments in small 
(neonatal) children (Zonnenberg et al., manuscript in preparation). In addition, 
bloodspot samples from children suffering from kwashiorkor or marasmus taken in 
Malawi (Africa) have been transported to our laboratory to be analyzed (Bandsma et al., 
manuscript in preparation), demonstrating its feasibility for field studies. It was also 
possible to use bloodspot sampling in studies  addressing cholesterol kinetics in mice, as 
shown by van der Veen et al. (24) and in very small children (van Meer et al., 
manuscript in preparation). 
 
Analytical Protocols  
Analytical methods had to be adjusted to the small sample sizes without changes in 
accuracy and reproducibility of the measurements. An important improvement in 
analytical procedures was the conversion of ParglcUA acid into Parglc as reported by 
Derks et al. (6). After enzymatic hydrolysis, the released glucose can be analyzed in the 
same way as blood glucose. Additionally, it provides the opportunity to calculate 
gluconeogenesis (GNG) flux to UDPglc using additional protocols. 
 
Hepatic Glucose Metabolism 
In our first study on hepatic carbohydrate metabolism, we used a rat model in which 
glucose-6-phosphate translocase was partially inhibited by the chlorogenic acid 
derivative S4048 (32-34). For this purpose, we adapted Mass Isotopomer Distribution 
Analysis (MIDA) algorithms as published by Hellerstein and Neese (35-38) to evaluate 
GNG directed to blood glucose or to hepatic glycogen. We were able to show that partial 
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inhibition of the translocase resulted in a 50% reduction in hepatic glucose production 
without any influence on GNG or glycogen phosphorylase flux (Chapter 5). 
At the time this experiment was designed, four tests were available to estimate 
gluconeogenic and non-gluconeogenic fluxes in vivo: 
1. 13C nuclear magnetic resonance spectroscopy using [1-13C]-glucose 
infusion protocols. 
2. recycling of glucose and glucose carbon using [U-13C]-glucose infusion 
protocols. 
3. incorporation of tritium or deuterium into glucose using tritiated or 
deutrated water, respectively. 
4. incorporation of 13C into glucose (and UDP-glucose) from infused [2-13C]-
glycerol.  
 
1. 13C Nuclear Magnetic Resonance Spectroscopy  
Glycogen concentration in the liver can be measured repetitively by 13C nuclear magnetic 
resonance spectroscopy in a noninvasive manner. In combination with magnetic 
resonance imaging to estimate liver volume, glycogen content in the liver can be 
calculated. The changes in glycogen content over time can be converted into glycogen 
turnover rates. GNG is calculated as the difference between glucose production rate and 
estimated hepatic glycogenolysis. This elegant method was first published by Rothman et 
al. in 1991 (39) Glycogen synthesis and simultaneous glycogenolysis can be estimated 
when sequential infusions of [1-13C]-glucose and unlabelled glucose are given (40). This 
method allows estimation of turnover rates of one of the precursors of blood glucose in 
the inaccessible hepatic pool, i.e., liver glycogen. In combination with calculated blood 
glucose turnover rates using isotope dilution algorithms, the absolute contribution of 
GNG to blood glucose can be estimated. Additionally, the flux from blood glucose to 
glycogen can be calculated and is taken as a measure of glycogen synthesis. However, 
the flux of GNG to glycogen can not be determined using this technique. Additionally, 
this technique requires the availability of expensive equipment. Details of this technique 
are beyond the scope of this thesis but are described in detail elsewhere (41-44). 
 
2.  Recycling of Glucose Molecules  
Blood glucose can be engaged in the flux through glycolysis → tricarboxylic acid (TCA) 
cycle → GNG. Katz and Tayek proposed a method to estimate GNG in which  
[U-13C]-glucose (M+6) is infused into the bloodstream (45-48) . After glycolysis, 
uniformly labelled pyruvate (M+3) is formed from which, within the TCA cycle  
(Chapter 2), 13C atoms can be exchanged for 12C atoms resulting in pyruvate containing 
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one or two 13C atoms. In GNG the labelled pyruvate will be converted to glyceraldehyde-
3-phosphate (G3P) and dihydroxyacetone phosphate (DHAP) in the triose phosphate 
pool. The condensation of these molecules yield one fructose-1,6-P2 (F16P) (Chapter 2) 
containing one to six 13C atoms. When enrichments are low, molecules containing four to 
six 13C atoms are present at negligible abundances in plasma. Therefore, only glucose 
molecules containing one (M+1), two (M+2), or three (M+3) 13C atoms can be measured. 
Since the sum of M+1, M+2, and M+3 represents the fraction of recycled glucose, M+6 
represents the fraction of infused label. Absolute GNG can be calculated as the product 
from fractional GNG and plasma glucose turnover rate, as described in Chapter 4 (Eq. 9). 
One of the first studies using this methodology was performed by Kalderon (49), 
who studied the cycling of [U-13C]-glucose in children suffering from glycogen storage 
disease type I and type III using this approach (50;51). The method was further refined 
by Katz et al. (45) and, in cooperation with Tayek, a number of equations were derived 
to determine parameters of glucose metabolism like glucose production, GNG, recycling 
of carbon atoms, and recycling of glucose molecules (46;47;52). Landau et al. 
challenged these calculations because of the underestimation of the “true GNG” due to 
the lack of steady-state in label distribution caused by dilution with unlabeled 
gluconeogenic substrates. Subsequently, Landau et al. introduced “corrected” equations 
(53). An alternative, the reciprocal pool model, was proposed by Haymond and Sunehag 
(54). Mao et al. used a long, primed-infusion protocol and showed that lack of isotope 
steady-state could account for a large part of the underestimation in GNG (55). 
We have tested a long infusion protocol (eight hours without the priming) in 
C57BL/6J mice as suggested by Mao et al. (40). As presented in Appendix 1A, an 
isotopically steady-state level of infused [U-13C]-glucose was achieved within 3 hours, 
whereas isotopically steady-state of singly, doubly, and triply labelled glucose was not 
achieved within the experimental period. Consequently, the calculated fractional GNG 
rose over time to 58% in isotopically steady-state, which is slightly lower than the 65% 
(unpublished data) and 68% (Chapter 6) that were calculated when MIDA protocols were 
used during 8 hour infusions. Using the equation of Haymond (54) in isotopically steady-
state, the fractional GNG exceeds 100% by far. These results imply that the 
underestimation of GNG might be the result of the lack of isotope equilibrium as 
suggested by Mao et al. (55) and correction factors used in some equations are needed 
to adjust for isotopically non-steady-state situations.  
 
3. Incorporation of Tritium or Deuterium into Glucose 
Rognstad et al. showed in 1974 for the first time that incorporation of tritium from 3H2O 
into glucose can be used to calculate the contribution of GNG in glucose production  
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in vitro (56). In 1991, these authors suggested that this protocol should also be suitable 
for use in in vivo experiments (57). The substitution of tritiated for deuterium-enriched 
water made in vivo experiments in rats (58;59) and in humans (60) more attractive. 
When body water of individuals is enriched with 2H2O (0.25 to 0.5%), deuterium 
will be incorporated at different positions of the glucose skeleton, depending on the 
metabolic processes (see also Chapter 2): 
[6-2H]-glucose (C6)  conversions of pyruvate to phosphenolpyruvate 
via oxaloacetate  
[5-2H]-glucose (C5)   conversion of dihydroxyacetone phosphate to 
glyceraldehyde-3-phosphate.  
[2-2H]-glucose (C2)  conversion of fructose-6-phosphate to 
glucose-6-phosphate  
The enrichments at the C5 and C6 positions in blood glucose represent GNG from 
glycerol and pyruvate, respectively, under the assumption that the labeling is complete 
and that there is no dilution of the label during the flux to G6P. Whereas the positional 
enrichment on C5 position is indeed complete (61;62), for C6 it varies from 65 to 80% 
(59;60;63), probably due to the influx of unlabelled molecules at the level of the triose 
phosphate pool. The incorporation of deuterium at the C2 position represents the GNG 
flux and the flux from glycogen to blood glucose under the assumption that F6P and G6P 
can be considered as a single pool. Therefore, the fractional contribution of GNG to 
glucose production can be calculated as the ratio of deuterium labeling at C5 and at C2 
positions. Because it has been shown that the fractional enrichment of deuterium at C2 
equals that of body water (61), the latter is often taken into the equations. Absolute GNG 
to blood glucose is calculated as the product of fractional contribution and its turnover 
rate calculated from isotope dilution algorithms and constant infusion protocols with 
[6,6-2H2]-glucose (see also Chapter 4). 
The major advantages of this protocol are related to the simplicity of experimental 
design and the relative low costs of the labelled compounds. Although over the years 
there has been hardly a debate concerning this protocol, very recently it was shown that 
deuterium enrichment at the C5 position might be influenced by transaldolase exchange 
and/or isotope effects at the level of the triose phosphate isomerase step (64) resulting 
in an overestimation of the C5 over C2 ratio. In the calculation of the absolute flux of 
GNG to blood glucose, it is assumed that isotopologues [5-2H]-glucose, [2-2H]-glucose, 
and [6,6-2H2]-glucose are metabolically identical. Unfortunately, very large volumes of 
blood are needed for analyses, which makes experimentation in small animals and 
children impossible. Additionally, with this protocol it is impossible to calculate GNG 
directed to glycogen. However, after analytical improvements, especially the conversion 
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of ParglcUA into Parglc as described by Derks et al. (6), this option can now be explored. 
Furthermore, the complicated and time-consuming chemical procedures (especially to 
form the hexamethylenetetramine molecule) that are used in these methods (60) can 
possibly be simplified by the analytical procedure presented by Chacko (65). 
 
4. Incorporation of 13C Labels from infused [2-13C]-Glycerol into Glucose 
Neese and Hellerstein (37) and also Peroni (66) argued in 1995 that glucose can be 
considered as a dimer of C-3 units, i.e., DHAP and G3P, generated from a number of 
precursors (like glycerol, alanine, lactate, and pyruvate) that are assembled to form 
F16P. By combinatorial algorithms it is possible to estimate the enrichment in the hepatic 
triose phosphate pool (precursor pool enrichment) from which enrichments in F16P 
present in the inaccessible hepatic pool can be derived. Subsequently, the fraction newly 
synthesized glucose in blood and newly synthesized hepatic UDPglc can be calculated 
(see also Chapter 4). Equations to calculate a large part of hepatic carbohydrate 
metabolism were first presented by Hellerstein in 1997 (35), by an approach called Mass 
Isotope Distribution Analysis (MIDA). This protocol provides the opportunity to estimate 
GNG fluxes to blood glucose as well as to hepatic glycogen, which is very attractive for 
studies addressing the metabolic consequences of glycogen storage diseases. In our first 
experiment (Chapter 5) we have adapted the protocols published by Hellerstein and 
Neese (35;37;67-69). Over the years, improvements were made with respect to infusion 
protocols and calculation algorithms. Calculations were adjusted according to isotope 
dilution algorithms that finally resulted in balanced input and output fluxes as discussed 
in Chapter 4.  
 
Discussion on Methodologies 
From the four protocols to estimate GNG discussed here, the MIDA protocol is likely the 
one most criticized in the literature. In the late nineties, criticism was mainly focussed on 
assumptions related to glycerol metabolism. Previs et al. argued that, to obtain 
“reasonable estimates” of the fractional GNG rate (87%) in 30 hour-fasted mice, very 
high infusion rates of glycerol would be needed (70). In our first experiments in mice, we 
have used such high infusion rates (Chapter 6). Mice fasted for 9 and 24 hours showed a 
similar fractional GNG rate (79 ± 5%). When we switched to low glycerol infusion 
protocols, as used by Derks et al. and Herrema et al. (6;7), fractional GNG rates in 9 
hour fasted mice were not much different (73 ± 2%). Additionally, Ackermans et al. 
showed that in healthy human volunteers an additional infusion of glycerol had no effect 
on carbohydrate fluxes nor on the fractional contributions of GNG to plasma glucose 
using the deuterium protocol (71). The combined results from mice and humans makes 
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the assumption that fractional GNG is modulated by the glycerol infusion rate less 
plausible.  
Landau et al. and Previs et al. presented data that suggest the existence of a 
zonation in precursor pool enrichment in perfused livers of long-term fasted rats (72;73) 
and, additionally, Previs et al. showed data to indicate that there are large variations in 
triose phosphate labelling of hepatocytes when exposed to the same amount of [U-13C]-
glycerol (74). These authors concluded that these observations might result in an 
underestimation of GNG as determined by the MIDA protocol. Siler et al. (75) countered 
this argument: first, several laboratories have reported “appropriate values” of fractional 
GNG using MIDA protocols; second, in literature a large variation in values for fractional 
GNG has been reported; third, the variations in estimation of fractional GNG were 
obtained with [U-13C]-glycerol instead of [2-13C]-glycerol which in itself tends to lead to 
an underestimation of GNG because of a loss of 13C-carbon via the pentose-phosphate 
cycle, as was shown by Kurland et al. (76). Liu, Rojek and colleagues (77;78) showed 
that aquaporin-9 is the major transporter for glycerol uptake by mouse erythrocytes and 
hepatocytes. Remarkably, the expression of this transporter in the liver is localized 
predominately in the perivenous zone. Therefore, hepatocytes closer to the hepatic 
artery, that are exposed to higher glycerol concentrations, have a lower capacity for 
uptake compared to hepatocytes in the perivenous area that are exposed to lower 
concentrations. This suggest that actual uptake may be similar in all hepatocytes, 
independent from their localization in the liver acinus. These observations are not 
consistent with the assumptions made by Landau et al. (79). 
We have experimentally tested the existence of a physiologically relevant gradient 
in precursor pool enrichment over the liver lobule in the bile diverted rat model described 
by Kuipers et al. (80). In this experiment, precursor pool enrichments and fractional 
contributions of GNG were calculated in plasma glucose, paracetamol glucuronic acid and 
bilirubin glucuronic acid isolated from both urine and bile. The infusion protocol was 
identical to that described in Chapter 5 (see Appendix 1B). Precursor pool enrichment 
derived from blood glucose and ParGlcUA sampled from the bile were 0.185 and 0.153, 
respectively, and the fractional contributions of GNG were identical (60%). Assuming 
that the two precursor pool enrichments represent the average of two zones situated 
next to each other in the lobule, the gradient across the liver lobule might range from 
0.140 to 0.200. From this, fractional synthesis rates calculated over this gradient have a 
range from 59.5 to 61.5% (table 1 Appendix 1B). This small range is in sharp contrast to 
the values deduced by Previs et al. (72).   
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Conclusions on Methodology 
The four different protocols discussed, all using stable isotope techniques, may give 
somewhat different results when performed under the same conditions. However, in 
some cases also comparable results have been obtained. There has been a lot of debate 
which protocol would give the “true” fractional synthesis of glucose. From a practical 
point of view, several issues in the debate concerning the MIDA protocol could be 
addressed in a satisfactory manner. The MIDA protocol gives the possibility to calculate 
hepatic carbohydrate fluxes from/to blood glucose, from/to glycogen and the fractional 
synthesis of glucose and UDPglc. In our opinion, experiments performed according to the 
presented (low dose) protocol give very reproducible results in hyper-, normo-, and 
hypoglycaemic mouse models. It can be performed in small animal species, as well as in 
small children because of the small sample sizes required. Analytical procedures are 
relatively easy to perform and are very reproducible. Isotopic steady-state is reached 
within three hours and holds for at least another three hours.  
 
Insulin Sensitivity of Glucose Metabolism 
To assess insulin sensitivity of glucose metabolism in vivo, a number of tests is available. 
Easy to perform is Homeostasis Model Assessments (HOMA index). This index uses the 
product of fasting glucose and insulin concentrations relative to the value in a population 
considered to have normal glucose and insulin responses (81). The major drawback of 
this index is that no conclusions can be drawn about the kind of perturbation in glucose 
metabolism underlying the changes in HOMA index, i.e., whether the liver or the 
peripheral organs are affected. The oral and intraperitoneal glucose tolerance tests 
(OGTT and IVGTT) and the intraperitoneal insulin tolerance test (IVITT) are somewhat 
more complicated but also more informative. In these tests, relatively large amounts of 
glucose (with or without stably labelled glucose) or insulin are administered to animals or 
human subjects to perturb glucose metabolism and subsequently measure the relaxation 
of the perturbed blood glucose concentration to its initial level. Complicated tests are the 
hyperinsulinaemic euglycemic clamp (HIEC), the hyperglycemic clamp (HGC), and the 
minimal model, but these are by far the most informative ones. 
 
Clamp Studies in Mice 
From the three tests mentioned, the HIEC is most often used. It involves a continuous 
infusion of insulin to introduce a high-physiological insulin concentration that is normally 
only present during postprandial periods. The high insulin concentration enhances blood 
glucose disposal into peripheral tissue and inhibits hepatic glucose production rates, 
resulting in a decrease of blood glucose concentration over time. The reduced glucose 
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concentration is, during the test, compensated for by infusion of glucose at a rate just 
sufficient to maintain euglycemia. The glucose infusion rate (GIR) at steady-state is a 
measure for total body insulin sensitivity; a higher value of GIR demonstrates that the 
total body is more sensitive to the actions of insulin.     
The use of HIEC was first reported by DeFronzo and colleagues in 1979 (82) to 
evaluate insulin sensitivity in humans. In 1983, the technique was adapted for use in 
rats by Burnol et al. (83) and Kraegen et al. (84), employing anaesthetized and 
conscious animals, respectively. Studies using HIEC techniques in (anaesthetized) mice 
were first reported by Veroni et al. in 1991 (85) and Marshall et al. in 1994 (86). More 
recently, the HIEC was combined with isotope dilution algorithms, which makes it 
possible to assess the total body insulin sensitivity as well as hepatic insulin sensitivity. 
This method is often considered as “the gold standard” to assess insulin sensitivity of 
glucose metabolism.   
Over the years, numerous protocols have been developed for HIEC, especially 
with respect to its use in mouse models (87). Unfortunately, the protocols are not always 
accurately documented (88), which makes interpretation of presented results 
cumbersome. Different conditions have been employed in published clamp studies: 
different fasting periods before the start of the experiment, duration of the experiment, 
use of conscious or anaesthetized mice during the test, conscious mice that were either 
restrained or not. All our experiments have been performed in unanaesthetized, freely 
moving mice. Handling of conscious mice is an important issue because it may have an 
effect on hormone levels, e.g., catecholamines, that interfere with glucose metabolism 
(88;89). A number of different infusion protocols have been described, i.e., constant 
infusion protocols and primed constant infusion protocols, and there are variations in the 
infusion rates of insulin. In some cases the infusion solutions contain additional 
substances, like somatostatin to block β-cell function. Care with interpretations of results 
has also to be taken when different strains of mice are involved, because large 
differences in glucose metabolism between mice strains have been reported (90).    
Our first clamp experiment in rats (see thesis Wiegman (91)) was adapted from 
published  protocols. For the first clamp experiment in mice (Chapter 7), this protocol 
was adjusted to MIDA protocols as were developed for mice including the use of 
experimental cages. These cages allowed to handle the tail of mice for a very short 
period of time to obtain a small blood sample from the tail tip. It has been shown that 
this procedure of sampling has a minor effect on catecholamine levels (88). The two 
separate infusion solutions that are used in HIEC experiments have to be mixed just 
before entering the bloodstream of the mouse. For this purpose, we introduced a special, 
low-volume mixing moiety (see Appendix 1) that can be attached on the skull with 
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acrylic glue, leaving a very small dead volume between the mixing tool and the heart 
where the jugular vein catheter ends. 
Duration of fasting is another important issue in this type of experiments. Ayala et 
al. (88) argued that mice that were fasted overnight (18 hours) have an increased insulin 
sensitivity compared to 5 hour fasted mice. A variety of behavioral and physiological 
adaptations in mice were seen, including body weight loss, increased appetite and 
spontaneous light cycle activity, reduced metabolic rate, and decreased heart rate and 
decreased blood pressure (92). In the HIEC protocol, we used a 9 hour fasting period 
prior to the experiment (Chapter 7) like in our MIDA experiments. The conscious and 
unrestrained animals received a constant insulin infusion at the rate of 10 mU.kg-1.min-1, 
i.e., 15 mU.h-1. Additionally, 40 µg.ml-1 somatostatin was added to inhibit pancreatic 
function. The second and variable infusate contained 300 mg.ml-1 glucose, from which 
3% was [U-13C]-glucose to avoid systematic errors in calculation, i.e., underestimation of 
glucose turnover rates due to insufficient mixing of endogenous and exogenous glucose 
(93;94). To prevent too high total infusion rates, the first solution contained 200 mg.ml-1 
glucose, from which 3% was [U-13C]-glucose. 
To establish our protocol, two tests have been performed prior to its introduction. 
Firstly, we determined the influence of insulin infusion rate on blood glucose kinetics. 
Secondly, we studied the differences in glucose kinetics between conscious, freely-
moving mice and anaesthetized mice. Both experiments are described in detail in 
Appendix 1C. In the first experiment, we were able to show that there was, as expected, 
a dose-dependent relationship between insulin infusion rate and the parameters of blood 
glucose kinetics, i.e., glucose infusion rate (GIR), glucose disposal rate (Rd), glucose 
production rate (Ra), and metabolic clearance rate (MCR). To our opinion, an insulin 
infusion rate of 6 mU.h-1 is preferable for experiments in mice because this allows to 
detect changes in metabolism to higher and lower rates. This conclusion was also drawn 
by Shen et al. (95) who calculated in a comparable experiment similar values for Ra and 
MCR at a comparable insulin infusion rate of 5 mU.kg-1.min-1. In the second experiment, 
one group of conscious, freely-moving mice received a continuous infusion of stable 
isotopically-labelled glucose for 3 hours. The second group was subjected to the HIEC 
protocol described above for the same period of time. The first period of 3 hours was 
followed by a second period of 3 hours in which the mice were anaesthetized  by an i.p. 
injection with a mixture of acepromazine, midzolam and fentanyl (doses: 6.25, 6.25, and 
0.31 mg.kg-1, respectively) while the infusion protocols were continued unchanged. As 
shown in Appendix 1D, blood glucose concentrations in the constant infusion group 
dropped significantly (35%) after introduction of anaesthesia. The kinetic parameters Rd, 
Ra and MCR were 55%, 55% and 29% lower, respectively, when anaesthesia was 
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compared to no anaesthesia. In the HIEC group, the GIR was reduced significantly 
(53%) when conscious mice were anaesthetized and, accordingly, Rd, Ra and MCR were 
respectively 57%, 67% and 57% lower under these conditions. Based on these major 
effects on blood glucose kinetics exerted by introduction of anaesthesia, we decided to 
perform all future tests exclusively in conscious, freely-moving mice using the HIEC 
protocol as described above. 
For the first protocol (Chapter 7), a relatively long infusion period (6 hours) was 
chosen, to reach isotopic and metabolic steady-states for accurate calculations of kinetic 
parameters. With growing experience, we were able to obtain isotopic and metabolic 
steady-state within 2 hours  that could be maintained for another 4 hours. This made it 
possible to introduce a protocol in which the HIEC was scaled-down to last for 3 hours 
from which the last hour represented the steady-state period. The 3 hours HIEC period 
can be preceded by a constant infusion protocol of 3 hours which allows to calculate 
basal blood glucose kinetics before hyperinsulinemic kinetics in individual animals 
(manuscripts in preparation). Spectacular improvements were made by combining the 
MIDA infusion protocol, i.e., 2-13C-glycerol, 1-2H-galactose, and paracetamol, with this 
basal/clamp protocol. This combination provides the possibility to evaluate peripheral 
and intrahepatic fluxes at basal and at high insulin levels in the same animal 
(manuscripts in preparation). For future experiments, we speculate that this 
methodology can also be used in hyperglycaemic clamp studies. 
In conclusion, HIEC protocols that were developed and evaluated over the years 
provide excellent tools to estimate insulin sensitivity and its influence on blood glucose 
kinetics and hepatic carbohydrate metabolism in small laboratory animals. However, it 
must be emphasized that the tests require complicated calculation algorithms and, with 
respect to mice, the requirement to implant a jugular vein catheter implies that these 
protocols can not be used for longitudinal long-term studies in individual animals.  
 
Whole Body Glucose Test 
To meet the demand of longitudinal studies, i.e., to assess time-dependent effects of 
diets or drug treatments in individual animals in time, we introduced the so-called Whole 
Body Glucose Test (WBGT) as is described in Chapter 9. A small amount of [6,6-2H]-
glucose (~5% of pool size) is introduced intraperitoneally in mice without disturbing 
blood glucose levels and, assumingly, blood glucose kinetics. The introduced label is 
absorbed into the blood compartment and subsequently eliminated from this pool, a 
process that can be described by a single-pool first order kinetic model. Parameters 
retrieved from the single-pool first order kinetic model can be used to calculate 
parameters that describe blood glucose metabolism. From insulin concentrations that are 
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measured at the end of the test and blood glucose concentrations, insulin sensitivity 
during the test can be calculated as a mouse-specific HOMA-index. This protocol has 
already been used in a number of mouse models (manuscripts in preparation). Recently, 
it has been shown that the delicate physical and metabolic systems in an arthritis mouse 
model are not disturbed when the WBGT was performed three times over a period of 
three weeks (Unpublished data in collaboration with Dr. W. Dokter, MSD, Oss). Readout 
parameters like fasting blood glucose levels, body weight and scores of arthritis in the 
tested mice were identical to a group that was not exposed to a WBGT during these 
three weeks (data not shown). We speculate that the methodology will also be feasible 
for use in humans. 
In contrast to clamp studies discussed previously, the WBGT is calculated at 
metabolic steady-state but at the same time at isotopic non-steady-state. This implies 
that different calculation algorithms have to be used to estimate kinetic parameters like 
Ra and MCR. In the procedure four kinetic parameters, shown in equation 57 of Chapter 
4, have to be estimated, i.e., the absorption rate constant (kab), the extrapolated 
concentration of the labelled glucose at t=0 (C0
ab), the elimination rate (kel) and the 
extrapolated label concentration at t=0 (C0
el). For this purpose, we used a numerical 
model in SAAM II software (Version 1.2.1 SAAM Institute, University of Washington) to 
fit these parameters to the measured data points. Next, a number of known parameters 
can be calculated, i.e., volume of glucose distribution (V), pool size (A) and, 
bioavailability (F) from which finally Ra and MCR can be deduced. Validity of and 
equations for this protocol are described in Chapter 4 and in Chapter 9.  
An important issue concerns the interpretation of parameters generated by WBGT. 
The algorithms for the isotopic non-steady-state calculations are essentially adapted 
from the field of pharmacokinetics. Whereas in pharmacological studies a xenobiotic is 
usually introduced into the blood compartment that is then eliminated over time. In 
WBGT, a labelled endogenous product is introduced which is, on top of being eliminated 
from the pool, also diluted over time due to the endogenous production. After labelled 
glucose has entered the blood compartment there is a constant dilution by unlabelled 
glucose resulting in a continuous decrease in the fractional contribution of the tracer over 
time. This dilution is a measure for glucose production rate, which during fasting, is 
accounted for glucose production by the liver. At each time point, the concentrations of 
the tracer are calculated from glucose concentrations and fractional contributions of the 
tracer. These concentrations decrease gradually over time (analogous to the decline of 
concentrations of xenobiotics in pharmacology) and so the elimination is a measure for 
glucose disposal, i.e., a peripheral parameter. At metabolic steady-state, the amount of 
glucose in the pool remains unchanged, and as a result, the rate constants for dilution 
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and elimination must be equal. From this, kel, V and in combination MCR are parameters 
for peripheral glucose uptake, where Ra is the parameter for glucose production rate. 
 
Protocols to determine Glucose Kinetics in Non-Steady-State Conditions 
A third possibility in which it can be relevant to assess blood glucose kinetics is during 
isotopic and metabolic non-steady-state conditions, e.g., after administration of an oral 
or intravenous glucose bolus. An often used protocol to study non-steady-state glucose 
metabolism was introduced by Steele et al. in 1956 and modified in 1959 (96;97). Over 
the years, it was adapted by many investigators, including ourselves, i.e., in Wielinga et 
al. (13), van Dijk et al. as shown in Chapter 8 (5) and by Brufau et al. (manuscript in 
preparation). However, there is some debate about this protocol, especially with respect 
to false negative values for endogenous glucose production that are sometimes obtained. 
This error is due to the estimates used for exchangeable pool (p) and volume of 
distribution (V) (shown in eq. 82 and 83 of Chapter 4). Because these parameters can 
not be calculated for each individual experiment it has to be estimated from separate 
experiments in a similar group of experimental animals/subjects. Cobelli et al. (98) and 
Mari et al. (99) did some effort to calculate these parameters for humans studies, 
whereas Proietto et al. (100) determined them for rat experiments. Over the years, 
these values have been copied to different experimental models in which they might not 
fit ideally and therefore introduce systemical errors. In Chapter 8, we were able to show 
that from the elimination of orally administered labeled glucose both parameters p and V 
can be calculated for each individual animal when it is demonstrated that the assumption 
of single-pool first order kinetics is valid. This procedure was discussed in detail for 
WBGT in Chapter 9.   
 
Modeling 
Isotopic protocols described above constitute powerful tools to obtain a better 
understanding of the physiology and pathophysiology of glucose metabolism within the 
body. The protocols consist of the introduction of stable isotopically-labeled compounds 
in carbohydrate pools of the body, i.e., blood glucose pool, hepatic UDP-glucose pool, 
and hepatic fructose-1,6-diphosphate pool. Sampling of compounds of interest is 
performed from accessible pools, i.e., blood glucose and urinary UDP-glucose. The 
fractional contributions of the stably labelled compounds are measured by mass 
spectrometry after which carbohydrate kinetics can be calculated according to isotope 
dilution algorithms. Subsequently, carbohydrate fluxes between labeling and sampling 
sites are deduced. However, the fluxes calculated with the models presented in this 
thesis represent only a part of total carbohydrate metabolism in the body.  
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For the interpretation of the whole carbohydrate metabolic system including 
inaccessible pools, a link has to be made between the information available from the 
accessible pools and the events occurring in the inaccessible pools. This requires a 
structural model based on known information and assumptions about the whole system. 
For analysis of these structural models, SAAM II software (Version 1.2.1 SAAM Institute, 
University of Washington) was used. 
A compartmental model was constructed to describe intracellular carbohydrate 
fluxes to explain delayed glucose absorption in Fxr-/- mice (Chapter 8). The model used 
was adapted from Stumpvoll et al. (101) and gave strong support for the proposed 
model of  intracellular carbohydrate metabolism in enterocytes, although it should be 
realized that it does not provide direct proof. For future exploration, it seems to be useful 
to translate the discussed model of hepatic carbohydrate metabolism (Chapter 4) into a 
compartmental model in which additional fluxes, i.e., glycolysis and the pentose 
phosphate flux, can be estimated.  
Relatively simple compartmental models can be transferred into so-called 
numerical models. An example of a numerical model is the estimation of blood glucose 
kinetics as described in the whole body glucose test in Chapter 9 and the oral glucose 




During the last couple of years, we have developed a number of models to estimate 
blood glucose kinetics and hepatic carbohydrate fluxes in small laboratory animals, such 
as rats and mice, using stable isotope techniques. Specifically for applications in 
(genetically-modified ) mice, surgical procedures were optimized and specialized tools for 
the experiments were developed, including experimental cages and mixing tools for 
multiple infusion protocols. The set-up during the day of experiment was carefully 
evaluated (like fasting time and period of the day, influence of anaesthesia, experimental 
area) and optimized. Furthermore, we succeeded to miniaturize sample sizes and were 
able to reduce infusion rates to allow for application of the procedures in mice. In 
addition, a simple protocol (WBGT) was developed to allow for longitudinal studies of 
blood glucose kinetics in individual mice. 
The studies conducted sofar, i.e., fluxomics in combination with genomics, 
proteomics and metabolomics, have significantly increased our knowledge of glucose 
metabolism in small laboratory animals. This combination of techniques allowed us to 
deduce information on control strength of a number of enzymes participating in the 
networks of  cellular and whole body carbohydrate metabolism. In the years to come, 
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application of the combined approaches will allow us to assess the (patho)physiological 
significance of newly identified genes in the development of metabolic diseases, to 
elucidate the metabolic consequences of (healthy) ageing and to assess the metabolic 
effects of novel drugs and diet components.  Importantly, since all the methodology is 
based on the use of stable isotopes, all the procedures that have been developed can 
directly be applied to humans, including young children and pregnant females, without 
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